41results about How to "Inhibition of production" patented technology

The invention relates to a kappa-carrageenin oligose selenizing derivate which has the following composition and structure: a single component n is equal to 1 to 30, and the average molecular weight of a mixed component is 800 to 6000 Da. The main steps of the preparation method of the kappa-carrageenin oligose selenizing derivate are as following: kappa-carrageenin is placed into acid to be heated and degraded, sodium selenite is added into degraded kappa-carrageenin oligose and is stirred for 2-hours at the temperature of 40 DEG C-70 DEG C-, acid in reaction products is neutralized, the reaction products are decompressed and concentrated, the distillated product is frozen, dried and decompressed, the crude products are purified by active carbon columns, and the purified products are frozen and dried to obtain fine products. The invention has mild reacting condition, and no toxic substance is generated.

The invention discloses eye cream. According to key points of the technical scheme, the eye cream is prepared from the following materials: water, polydimethylsiloxane/vinyl polydimethylsiloxane cross-linked polymer, cyclic penta polydimethylsiloxane, vinyl polydimethylsiloxane/polymethylsiloxane silsesquioxane cross-linked polymer, polydimethylsiloxane (polyethylene glycol) PEG-10/15 cross-linked polymer, polydimethylsiloxane, glycerin, CI47005, phenyl polytrimethylsiloxane, sodium chloride, phenoxyethanol, methyl hydroxybenzoate, propyl hydroxybenzoate, salidroside extract, avena sativa kernel extract, centella extract and lavender oil. Compared with the traditional formula, the eye cream has the advantages that multiple plant extracts are added, sufficient nutrients and moisture are supplemented to eyes, elasticity of skins of the eyes is restored, metabolism of cells of the eyes is promoted, and the effect of solving the problems of black eyes, pouch, wrinkles of the eyes and the like is realized, so that the eye cream can solve multiple problems of the eyes and is economic and practical.

The invention discloses a novel 2,5-dyhydroxy-p-phthalamide compound (I) and pharmaceutically acceptable salts thereof, a preparation method of the compound and application in preparing medicine treating and/or preventing nervous system related diseases. The diseases include but not limited to the vascular dementia, presenile dementia, Parkinson's disease, Huntington's disease, HIV related Alzheimer disease, nerve injuries caused by the traumatic brain injury and other diseases. The formula is defined in the description.

The invention discloses a class of novel salicylamide compounds (I) and a pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof, and applications of the novel salicylamide compounds (I) and the pharmaceutically acceptable salt thereof in preparation of drugs for treating and/or preventing nervous system related diseases, wherein the diseases include but are not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma, cerebral arterial thrombosis, cerebral hemorrhagic stroke, nerve injury caused by cerebral trauma and the like.

The invention relates to a composition capable of promoting insulin secretion and inhibiting generation of advanced glycosylation end products. The composition comprises the following components in percentage by mass: 5-95% of proanthocyanidin extract and 5-95% of dihydrochalcone. The main component of the proanthocyanidin extract is proanthocyanidin which accounts for 50-70% of the mass of the extract. The composition lays a foundation for the production of the future compound medicines, is beneficial to controlling blood sugar of diabetics and preventing and treating diabetic complications. The composition of the invention has the advantage that the multifunctional synergistic effect is obviously superior to effect of each independently used component.

The invention discloses application of pingyangmycin combined sodium hyaluronate in a medicine for treating venous malformation and a medicine for treating venous malformation, in particular relates to a medicine for treating venous malformation of head and neck. The molecular weight of the sodium hyaluronate is 600,000-1,500,000 Dalton; the concentrations of the pingyangmycin and the sodium hyaluronate are 10 mg/mL and 400 mug/mL respectively.

The invention discloses a type of novel 3-amino alkyl phthalein compound (I) as well as a pharmaceutical acceptable salt, a preparation method, a medicine composition and application thereof in preparing medicines for treating and/or preventing diseases associated with nervous systems, and the diseases comprise but not limited to, vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV (human immunodeficiency virus) related dementia, multiple sclerosis, muscular atrophy amyotrophic lateral sclerosis, neuropathic pain, glaucoma, ischemic stroke, hemorrhagic stroke, nerve damage caused by brain injury, and the like.

The invention relates to a fusion protein with a recombinant collagen binding structure domain. The amino acid sequence of the fusion protein is shown in SEQID NO:2. The fusion protein is a solution preparation and can be used for preparing antitumor drugs, and the drugs can be administrated by being locally injected in an neoplasm with enough therapeutic dosage at a time. In the fusion protein, a local slow release system formed by the collagen binding structure domain CBD well avoids a strong immune response caused by diffusion of IFN-gamma to surrounding tissues. At the same time, repeated administration of the drugs is not required; not only the pain, brought by traumas caused by constant repeated administration of the drugs, of patients is reduced and the high therapy cost caused by the constant repeated administration of the drugs is reduced, but also the toxic and side effects caused by the large use amount and frequent use of the drugs are reduced.

The invention discloses novel hydroxyflurbiprofen mannich base compounds (I) as well as pharmaceutically acceptable salts thereof, a preparation method, pharmaceutical composition and applications inthe preparation of drugs for treating and/or preventing neurodegenerative associated diseases, including but not limited to vascular dementia, AD (Alzheimer's disease), Parkinson's disease, Huntington's disease, HIV-associated dementia, MS (multiple sclerosis), progressive lateral sclerosis of spinal cord, neuropathic pains, glaucoma and other neurodegenerative diseases.

The invention provides a dietary supplement which comprises, by weight pars, 50-70 parts of catechol, 16-24 parts of withania omnifera ketone extract, 8-12 parts of withaferin extract and 6-14 parts of piperine. The dietary supplement may further comprise nutraceutically and/or pharmaceutically acceptable carriers and/or adjuvants to make oral dosage forms. The dietary supplement has excellent anti-inflammatory and anti-oxidant effects and can be further used for preparing health care products and medicines.

The invention discloses an application of marine chlorella polysaccharide in the preparation of a medicine for inhibiting tumor angiogenesis. The marine chlorella polysaccharide is abundant in source of raw materials and low in cost; the effective concentration of the extracted marine chlorella polysaccharide in body fluid at the infected part is 12.5-200g/ml, the marine chlorella polysaccharide has obvious inhibition effect on the proliferation and migration of vascular endothelial cells, and therefore, the marine chlorella polysaccharide can inhibit the tumor angiogenesis and be developed to a medicine for inhibiting tumor migration, a health-care food, a food additive and the like.

The invention discloses benzyl aminyl flurbiprofen amides compounds (I) as well as pharmaceutically acceptable salts and a preparation method thereof, a medicine composition and use thereof in preparation of medicines for treating and/or preventing nervous system-related diseases including but not limited to vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV-associated dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma, ischemic stroke, hemorrhagic stroke and nerve damage caused by traumatic brain injury.

The present invention discloses a human Gremlin 1 chimeric vaccine for treating liver fibrosis, and applications thereof, wherein human Gremlin 1 B-cell epitope is inserted into the c/e1 epitope of hepatitis B virus core antigen to construct the human Gremlin 1 chimeric vaccine capable of assembling hepatitis B virus core particles. According to the present invention, the chimeric vaccine can stimulate the body to produce high-titer anti-human Gremlin 1 neutralizing antibody without adjuvant assisting; with the application of the chimeric vaccine to immunize mice, the mice are induced to produce anti-Gremlin 1 antibodies so as to neutralize the cytokine Gremlin 1 over-expressed during the CCl4-induced liver fibrosis process and inhibit the promoting effect of the cytokine Gremlin 1 in the liver fibrosis development process, such that the liver fibrosis process develop is inhibited to a certain extent; and the results confirm that the CCl4-induced mouse liver fibrosis can be significantly inhibited after the Gremlin 1 recombinant protein vaccine is used to immunize mice, and the Gremlin 1 vaccine is expected to be a simple, safe, and effective new method for prevention and treatment of liver fibrosis.

The present invention provides a nutrition supplementing agent, which comprises a moringa oleifera extract, hydroxytyrosol and piperine, and can further comprises a nutraceutically and/or pharmaceutically acceptable carrier and/or an auxiliary material so as to be prepared into an oral dosage form. According to the present invention, the nutrition supplementing agent has excellent anti-oxidation effect and excellent anti-inflammatory effect, and can be used for preparing health products and medicines.

The present invention provides a dietary supplement. The dietary supplement comprises 65-85 parts of a moringa oleifera extract, 5-12 parts of hydroxytyrosol, 5-12 parts of oleuropein and 5-11 parts of piperine. The dietary supplement can further comprise a nutraceutically and/or pharmaceutically acceptable carrier and/or accessories to be prepared into oral dosage forms. A preparation method of the dietary supplement is as follows: according to a preset ratio, the moringa oleifera extract, hydroxytyrosol, oleuropein and piperine are prepared; and the moringa oleifera extract, hydroxytyrosol, oleuropein and piperine are mixed. The dietary supplement has excellent anti-oxidant and anti-inflammatory effects and can be used for preparing health-care products and medicines.